Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

  • STATUS
    Recruiting
  • participants needed
    400
  • sponsor
    Synairgen Research Ltd.
Send
Updated on 1 February 2023
See if I qualify
cancer
body mass index
fever
renal disease
cardiovascular disease
asthma
hypertension
dyspnea
antiviral drugs
pulmonary function tests
chronic disease
chronic obstructive pulmonary disease
COPD
cough
liver disease
immunodeficiency
covid-19
SARS
interferon
lung disease
middle east respiratory syndrome
acute respiratory syndrome (sars)

Summary

SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-). IFN- in produced in the lungs during viral lung infections. It has been shown that older people and people with some chronic diseases have an IFN- deficiency. Many viruses inhibit IFN- as part of their strategy to evade the immune system.

Addition of IFN- in vitro protects lung cells from viral infection. IFN- protects cells against the MERS and SARS coronaviruses (close relatives of SARS-CoV-2, the virus that causes COVID-19).

SNG001 is an inhaled formulation of interferon beta-1a it is currently in Phase II clinical trials for COPD patients.

Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has:

  • been well tolerated during virus infections
  • enhanced antiviral activity in the lungs (measured in sputum and blood samples)
  • provided significant lung function benefit over placebo in asthma in two Phase II trials.

Synairgen believes SNG001 could help prevent worsening or accelerate recovery of severe lower respiratory tract illness in COVID-19 patients.

Patients who are in hospital or non-hospitalised but are a high risk groups (e.g. elderly or diabetics) will be invited to take part in the trial. The patient would receive either SNG001 or placebo once daily for 14 days. The severity of the patients condition would be recorded on a scale developed by the World Health Organisation and the patient would be asked questions about their breathlessness, cough and sputum every day, as well as assess their general medical condition and safety.

If SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.

Details
Condition SARS-CoV-2
Age 18years - 100years
Treatment Placebo, Interferon beta 1a
Clinical Study IdentifierNCT04385095
SponsorSynairgen Research Ltd.
Last Modified on1 February 2023

Eligibility

 Yes No Not Sure

Inclusion Criteria

Positive virus test for SARS-CoV-2 using RT-PCR or positive point-of-care viral infection test in the presence of strong clinical suspicion of SARS-CoV-2 infection
Male or female, 18 years of age at the time of consent
Patients admitted to hospital due to the severity of their confirmed or suspected COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes, a chronic lung condition, cancer, or frontline healthcare workers. (The Sponsor will inform sites as to whether non-hospitalised patients are to be entered into the trial)
Provide informed consent
Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception

Exclusion Criteria

> 24 hours after confirmation of SARS-CoV-2 infection by RT-PCR test
Any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation
Current or previous participation in another clinical trial where the patient has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study
Ventilated or in intensive care
Inability to use a nebuliser with a mouthpiece
History of hypersensitivity to natural or recombinant IFN- or to any of the excipients in the drug preparation
Patients that are taking an antiviral treatment (e.g. zanamivir or oseltamivir) prior to randomisation and/or on the day of randomisation
Female who are breast-feeding, lactating, pregnant or intending to become pregnant
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
body mass index
fever
renal disease
cardiovascular disease
asthma
hypertension
dyspnea
antiviral drugs
pulmonary function tests
chronic disease
chronic obstructive pulmonary disease
COPD
cough
liver disease
immunodeficiency
covid-19
SARS
interferon
lung disease
middle east respiratory syndrome
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.